Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

Dr. Scherer’s commitment to oncology patients took him from medical practice to research to helming 3T Biosciences, which is developing a novel T cell targeting platform.

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

In the life sciences sector, maintaining a strategic approach to tax planning has become increasingly complex, especially with ongoing regulatory changes affecting mergers, acquisitions, and how we ...

In 2021, I explored the impact of COVID-19 on the biotech sector in the article “Private Equity and SPACs in the Biopharma and Biotech Landscape.” The results were surprising: In 2024, global ...

Senti Bio cofounder and CEO Tim Lu, MD, Ph.D., a Harvard and MIT engineer by training, invented a “logic gating” technology to reduce cell therapy toxicities in oncology. Logic gating, an electrical ...

Managing third-party risk is one of the most arduous challenges facing pharmaceutical companies, and regulatory requirements are just one piece of this puzzle. Pharmaceutical organizations are ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...

Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, ...